Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mannkind Corp (MNKD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 298,561
  • Shares Outstanding, K 187,774
  • Annual Sales, $ 27,860 K
  • Annual Income, $ -86,980 K
  • 60-Month Beta 2.69
  • Price/Sales 10.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.13
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.46 +9.59%
on 04/18/19
2.17 -26.27%
on 03/25/19
-0.53 (-24.88%)
since 03/22/19
3-Month
1.15 +39.13%
on 01/30/19
2.34 -31.62%
on 03/20/19
+0.33 (+25.98%)
since 01/23/19
52-Week
0.94 +70.21%
on 12/27/18
3.04 -47.37%
on 09/05/18
-0.11 (-6.43%)
since 04/23/18

Most Recent Stories

More News
Detailed Research: Economic Perspectives on MannKind, Sonic Automotive, Five Prime Therapeutics, CONMED, Cohu, and FTI Consulting -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD),...

FCN : 79.00 (+0.52%)
FPRX : 12.52 (+5.83%)
COHU : 14.82 (+0.68%)
SAH : 15.38 (+1.79%)
CNMD : 80.76 (+2.05%)
MNKD : 1.60 (+0.63%)
MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension,...

MNKD : 1.60 (+0.63%)
MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the...

UTHR : 104.31 (+5.53%)
MNKD : 1.60 (+0.63%)
Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance

Veeva Systems (NYSE:VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the...

VEEV : 136.54 (+1.85%)
KPTI : 4.98 (+2.68%)
MNKD : 1.60 (+0.63%)
MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly

MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind...

MNKD : 1.60 (+0.63%)
MannKind Corporation to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 26, 2019 / MannKind Corporation (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 9:00 AM...

MNKD : 1.60 (+0.63%)
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20,...

MNKD : 1.60 (+0.63%)
MannKind Corporation Participating at Upcoming Conferences

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension,...

MHMNF : 54.5000 (unch)
MNKD : 1.60 (+0.63%)
MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019

MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019 and its management will host a conference call to discuss the financial...

MNKD : 1.60 (+0.63%)
Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD),...

BDC : 58.60 (+1.95%)
VRTV : 27.83 (+3.11%)
IEX : 156.19 (+1.69%)
MNKD : 1.60 (+0.63%)
DOOR : 50.66 (+1.06%)
BFAM : 128.07 (+1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade MNKD with:

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

2nd Resistance Point 1.67
1st Resistance Point 1.64
Last Price 1.60
1st Support Level 1.55
2nd Support Level 1.49

See More

52-Week High 3.04
Fibonacci 61.8% 2.24
Fibonacci 50% 1.99
Fibonacci 38.2% 1.74
Last Price 1.60
52-Week Low 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar